New York State Common Retirement Fund Sells 8,539 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

New York State Common Retirement Fund trimmed its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 1.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 468,563 shares of the medical equipment provider's stock after selling 8,539 shares during the quarter. New York State Common Retirement Fund owned approximately 0.13% of Intuitive Surgical worth $232,065,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the stock. Platform Technology Partners acquired a new position in Intuitive Surgical in the 1st quarter valued at approximately $359,000. Arizona State Retirement System increased its position in Intuitive Surgical by 1.4% in the 1st quarter. Arizona State Retirement System now owns 104,450 shares of the medical equipment provider's stock valued at $51,731,000 after acquiring an additional 1,442 shares during the period. Realta Investment Advisors increased its position in Intuitive Surgical by 3.1% in the 1st quarter. Realta Investment Advisors now owns 2,269 shares of the medical equipment provider's stock valued at $1,124,000 after acquiring an additional 69 shares during the period. Ballentine Partners LLC increased its position in Intuitive Surgical by 9.9% in the 1st quarter. Ballentine Partners LLC now owns 4,413 shares of the medical equipment provider's stock valued at $2,186,000 after acquiring an additional 398 shares during the period. Finally, Berbice Capital Management LLC boosted its stake in shares of Intuitive Surgical by 400.0% in the 1st quarter. Berbice Capital Management LLC now owns 250 shares of the medical equipment provider's stock valued at $124,000 after purchasing an additional 200 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the business's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the transaction, the executive vice president directly owned 2,245 shares of the company's stock, valued at approximately $1,152,089.10. The trade was a 43.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Robert Desantis sold 188 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $515.91, for a total transaction of $96,991.08. Following the transaction, the executive vice president directly owned 5,224 shares in the company, valued at approximately $2,695,113.84. The trade was a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,998 shares of company stock valued at $2,611,577 in the last 90 days. 0.70% of the stock is owned by company insiders.

Analyst Ratings Changes

ISRG has been the topic of a number of analyst reports. Royal Bank Of Canada reduced their price objective on shares of Intuitive Surgical from $630.00 to $605.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 23rd. Citigroup reaffirmed a "buy" rating and issued a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a research note on Thursday, May 22nd. Erste Group Bank raised shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. Truist Financial reduced their price objective on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Intuitive Surgical from a "hold" rating to a "sell" rating and cut their target price for the stock from $515.00 to $440.00 in a research note on Monday, June 9th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $592.86.

Intuitive Surgical Trading Up 0.9%

Shares of ISRG stock traded up $4.38 during trading hours on Monday, hitting $516.44. 2,082,717 shares of the company's stock were exchanged, compared to its average volume of 1,683,687. Intuitive Surgical, Inc. has a 12-month low of $413.82 and a 12-month high of $616.00. The business's 50 day simple moving average is $537.85 and its 200-day simple moving average is $536.67. The company has a market capitalization of $185.10 billion, a PE ratio of 75.72, a PEG ratio of 5.43 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.71 by $0.10. The company had revenue of $2.25 billion for the quarter, compared to the consensus estimate of $2.19 billion. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. During the same period in the previous year, the firm earned $1.50 earnings per share. Equities analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.